Posted by Michael Wonder on 17 May 2023
Bayer receives US FDA fast track designation for asundexian atrial fibrillation program
16 May 2023 - The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries.
Bayer today announced that the US FDA has granted fast track designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation.
